Key result
Aspirin resistance is influenced by multiple clinical and genetic factors, and elevated urinary 11-dehydrothromboxane B2 levels serve as an independent prognostic marker for cardiovascular events.
Why the study?
The effectiveness of aspirin and personalization of antiplatelet therapy remain crucial issues in cardiology, as evidence does not support aspirin for primary prevention in the general population.
Understanding the mechanisms and risk factors of aspirin resistance, along with utilizing diagnostic markers like 11-dehydrothromboxane B2, is crucial for personalizing antiplatelet therapy in cardiovascular disease.
Acetylsalicylic acid (aspirin) is one the most widespread drugs in the world. It is used for secondary prevention of atherothrombotic events in patients with cardiovascular disease. Accordingly, the problem of the effectiveness of aspirin treatment is among the crucial issues of cardiology. The issue of personalization of antiplatelet therapy remains relevant, since there is no convincing evidence in favor of using aspirin for primary prevention in the general population. In this review, recent data on aspirin resistance are considered. Potential mechanisms of non-responsiveness to aspirin, the role of genetic factors, standardization of tests and diagnostic criteria for aspirin resistance, and the treatment options are discussed. The data on the clinical and prognostic value of 11-dehydrothromboxane B2 as a promising marker of thromboxane-dependent platelet activation are analyzed.
No takes yet. Share an insight, caveat, or question.
Lukianets et al. (2020) conducted a review in Aspirin resistance in cardiovascular disease. Acetylsalicylic acid (aspirin) was evaluated. Aspirin resistance is influenced by multiple clinical and genetic factors, and elevated urinary 11-dehydrothromboxane B2 levels serve as an independent prognostic marker for cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: